For example, in several studies, insulin therapy with detemir resulted in less weight gain and a lower rate of hypoglycemia compared to therapy with glargine among patients with type 2 diabetes [8–13], suggesting that detemir may not be as potent as glargine. The gene discussed is INS; the disease is type 2 diabetes mellitus.